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Abstract 
Adenosine 5'-(1-thiotriphosphate) (ATPceS) binds to about 25000 high affinity sites in platelets (K a ~ 3 nM), competes fully in 
inhibiting the binding of ADP and, despite the absence of a specific photoactivatable substituent, is directly photoincorporated into a 
specific 18 kDa domain beginning at Tyr-198 in the c~ chain of glycoprotein lib (GPllbc~) following ultraviolet irradiation of fresh 
unfixed platelets (Greco et al. (1991) J. Biol. Chem. 266, 13627-13633). 8-azido ATP has now been shown to have similar binding 
parameters (K a 8 nM, 20000 sites/platelet) but, in this case, photoincorporation occurred equally in GPIIb and GPIIIa. To determine the 
possible function of GPIIbc~ in ADP-induced activation, platelets were isolated from two Glanzmann's thrombasthenia p tients whose 
platelets contain ~ 6% of normal levels of GPIIb. ADP and ATPo~S bound to intact, formaldehyde-fixed Glanzmann's platelets at high 
affinity sites with dissociation constants of ~ 30 nM and ~ 2 nM, respectively. Both nucleotides also bound to low affinity sites with 
dissociation constants of ~ 2 /xM: these values are similar to those obtained with control platelets. ATPc~S antagonized the shape 
ADP-induced shape change response of Glanzmann's platelets (EC50 5/xM) indicating that it bound to the P2T (ADP) receptor. However, 
photoincorporation was low (~ 7% of control) similar to their content of GPIIbc~. These results show that ADP binding and 
photoincorporation are occurring at different sites on the platelet surface but suggest hat the ADP binding site may be located in 
proximity to GPIIbce. 
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1. Introduction 
Under appropriate conditions, ADP released from dam- 
aged cells and tissues can give rise to a primary wave of 
platelet activation, inhibition of adenylyl cyclase, and the 
release of ADP from platelet dense granules. Primary 
activation and release of ADP can also be induced by other 
agonists such as thrombin or collagen. In both cases, the 
released ADP can then react further with platelets to 
induce a secondary wave of activation. These effects in 
platelets are thought o be mediated by surface receptors 
that are designated P2v in the purinergic receptor classifi- 
cation system since they recognize ADP as an agonist and 
ATP as an antagonist, although ATP acts as an agonist at 
other types of P2 receptors [1]. Despite its importance in 
Abbreviations: ATPo~S, adenosine 5'-(1-thiotriphosphate); 8-azido 
ATP, 8-azido-5'-adenosine triphosphate; SDS-PAGE, sodium dodecyl 
sulfate-polyacrylamide g lelectrophoresis; GPIIb/IIIa, glycoprotein 
IIb/Illa. 
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hemostasis, the platelet ADP receptor has not been charac- 
terized and it has not been resolved whether a single type 
of receptor mediates both activation and inhibition of 
elevated adenylyl cyclase or whether there are two distinct 
types of receptors one of which mediates activation and 
the other the inhibition of elevated adenylyl cyclase (for 
reviews, see [1-3]). 
A difficulty in carrying out equilibrium nucleotide bind- 
ing studies in fresh platelets is that steady state conditions 
cannot be achieved because of complications arising from 
nucleotide metabolism and secretion of ADP from stimu- 
lated platelets. To avoid these complications, we have used 
formaldehyde-fixed platelets as a test system to obtain 
steady state binding parameters for ADP and other nu- 
cleotides and then have compared these binding data with 
the potency of these compounds as examined in fresh 
platelets [4-7]. Both high and low affinity binding sites 
were found for the 20 nucleotides examined in the fixed 
platelet system, the highest affinity (K d 3 ___ 0.1 nM) being 
exhibited by adenosine 5'-(1-thiotriphosphate) (ATPaS). 
Using fresh unfixed platelets, we then showed that ATPo~ S 
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could be photoincorporated into a single component by 
direct irradiation with ultraviolet light in the absence of 
any specific photolabile substituents in the nucleotide [7]. 
The site of incorporation was shown to be in the a-chain 
of glycoprotein IIb (GPI][b), specifically within an 18 kDa 
domain beginning at Tyr-198. We have also shown that 
binding is of relatively low specificity with regard to 
nucleoside structure and that a range of purine and pyrimi- 
dine nucleoside triphosphates yield similar binding param- 
eters and degrees of photoincorporation [6]. An advantage 
of using the nucleoside triphosphates and thiotriphosphates 
is that they bind to platelets with high affinity and are 
antagonists of ADP-induced platelet activation so that 
interpretation f photoincorporation patterns is not compli- 
cated by membrane changes that might be associated with 
platelet activation. 
Although these studies clearly established GPIIba as 
the site of nucleotide photoincorporation, it was difficult to 
reconcile a role for GPIIba as a possible ADP receptor 
with the fact that pre~ious reports have indicated that 
Glanzmann' s thrombastl:Lenia platelets, which are markedly 
deficient in GPIIba, show normal shape change and eleva- 
tions in [Ca2+]i in response to ADP [8,9]. Furthermore, 
platelet GPIIba was not labelled by the photoaffinity 
analogue 2-(p-azidophenyl)ethylthioadenosine 5'-phos- 
phate (AzPet-ADP) [10]. On the other hand, incorporation 
of GPIIb/IIIa into liposomes has suggested a role for this 
integrin in Ca 2+ transport [11] and other studies have 
indicated decreased serotonin release, thromboxane B2 
synthesis and [Ca2+] i changes in thrombasthenic platelets 
suggesting defects in ADP-induced responses [ 12,13]. 
In order to resolve these discrepancies and to evaluate 
the possible role of GPIIba in ADP-induced platelet acti- 
vation, we have examined ATPa S binding and its photoin- 
corporation using Glanzmann's thrombasthenia platelets. 
Our results suggest that the ADP receptor is distinct from 
GPIIba but may be located in sufficiently close proximity 
to it that bound ADP can be photoincorporated into the 
GPIIb/IIIa complex in normal platelets. 
2. Methods 
The source and purity of reagents used has been previ- 
ously described [6,7]. Unlabeled 8-azido-5'-adenosine 
triphosphate (8-azido AFP) was obtained from Sigma and 
8-azido-5'-adenosine [y-32p]triphosphate (5 Ci/mmol) of 
greater than 95% purity was from ICN Biomedicals (Costa 
Mesa, CA). All other radiolabeled compounds were from 
Dupont-New England Nuclear. 
Normal human platelets were prepared from volunteer 
blood donations anticoagulated with citrate-phosphate-dex- 
trose-adenine, as previously described [6]. Citrated whole 
blood from two patient:; with Type I Glanzmann's throm- 
basthenia (patient 1, NL; patient 2, MM) [14] was kindly 
provided by Dr. Margaret Johnson and Mr. Robert Abel, 
Christiana Hospital, Wilmington, DE and processed to gel 
filtered or washed platelets. 
2.1. Binding studies 
The filtration technique using a Brandel cell harvester 
for measuring steady state nucleotide binding parameters 
in fixed platelets has been previously described [4,7]. The 
ratio of bound/total nucleotide was kept at < 0.1 and 
binding was determined after 15 min incubation. As previ- 
ously reported [5-7], platelets were treated with 4% para- 
formaldehyde (4° C, 48 h). In addition, we have obtained 
binding data with platelets fixed with 1% paraformal- 
dehyde for 30 rain at 4 ° C which are the conditions rou- 
tinely used in flow cytometric evaluation of platelet anti- 
gens. Binding studies with 8-azido ATP were carried out 
in semi-darkness. 
2.2. Shape change 
Shape change of gel-filtered platelets (1.5 • 108/ml) in 
the absence of added fibrinogen was evaluated in a total 
volume of 400/xl in a Payton Dual Channel aggregometer 
(Payton Associates, Buffalo, NY). Platelet rich plasma (5 
ml) was applied to a 50 ml Sepharose 2B column equili- 
brated in Tyrode' s-Hepes. The void volume was collected 
and the platelets tested for their ability to undergo shape 
change with ADP. Only isolated platelets that did not 
aggregate with 10 /zM ADP alone (i.e., were free from 
plasma fibrinogen) were used for shape change experi- 
ments. 
2.3. Photoaffinity labeling 
In brief, unfixed washed platelets (1 • 108) in the pres- 
ence of 1 /xg/ml PGE~ and in the absence of bovine 
serum albumin were incubated for up to 5 min at 0 ° C with 
85 nM [35S]ATPaS [6,7], an amount equal to 30-times the 
K d of high affinity ATPa S binding to fixed platelets [7], 
and were then irradiated at 360 /zW/cm 2 (254 nm) for an 
additional 5 min at 0 ° C. Platelets were recovered by 
centrifugation (12000 × g, 2 rain) and solubilized in 1% 
Triton X-100 in a buffer of 50 mM Tris, pH 7.4 containing 
as protease inhibitors leupeptin (50 /zg/ml), phenyl- 
methylsulfonyl fluoride (2 mM) and benzamidine (2 raM). 
Insoluble material was removed by centrifugation (217 000 
X g, 30 min) and the supernatant and insoluble (cyto- 
skeleton-associated) fractions were separately analyzed by 
7% SDS-PAGE and subsequent autoradiography. 
A similar procedure was used to measure the photoin- 
corporation of 8-azido [32 P]ATP (25-800 nM) into washed 
unfixed control platelets. 
2.4. Protein blotting 
Proteins were separated by 7% SDS-PAGE and elec- 
trophoretically transferred to 0.45 /~m nitrocellulose in a 
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semidry Western blot apparatus (E and K Scientific Prod- 
ucts, Saratoga, CA) (2.5 mA/cm 2 for 1 h) or in a Bio-Rad 
Trans Blot Apparatus (50 mA/13-16 h then 100 mA for 
1-2 h). Unoccupied binding sites on the nitrocellulose 
were blocked (2 h, 22 ° C) with 2% bovine serum albumin 
in Tris-buffered saline (10 mM Tris, 150 mM NaCI, pH 
7.5) before incubation (2 h, 22 ° C) with a polyclonal anti 
GPIIb/IIIa antiserum (1:1000 dilution) kindly provided by 
Dr. Leo Lin (Cetus Corporation). After extensive washing 
of the nitrocellulose membranes, ]25I-protein A (0.95 /xCi) 
was added and the membranes incubated (1 h, 22 ° C) to 
visualize GPIIb. Protein A (Sigma) was iodinated 
(Iodobeads, Pierce, Rockford, IL) in phosphate-buffered 
saline (140 mM NaC1, 2.7 mM KCI, 10 mM Na2HPO 4, 
1.8 mM KH2PO4, pH 7.35) to a specific activity of 2 
/xCi//~g. Autoradiographs of photoaffinity labeling and 
Western blotting experiments were scanned using an LKB 
soft-laser densitometer. 
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Fig. 1. Shape change in gel-filtered Glanzmann's  platelets. Shape change 
response induced by 2.5 /xM ADP (curve 1) was inhibited by increasing 
concentrations of ATPc~ S (curve 2, 2 .5 /xM;  curve 3, 5 /xM;  and curve 4, 
10/zM).  These results were identical to results obtained using gel-filtered 
normal platelets in the absence of exogenous fibrinogen. 
3.2. Binding studies 
3. Results 
3.1. Effect of ATPolS on shape change 
As previously reported [9], Glanzmann's thrombasthe- 
nia platelets howed a normal shape change response to 
2.5 /~M ADP. We showed that this response was antago- 
nized by ATPaS (Fig. 1) with an IC50 of ~ 5/xM similar 
to that previously seen with normal platelets uggesting 
that ATPaS could be used for direct photoincorporation 
studies with Glanzmann's platelets [6,7]. We have con- 
firmed the previous report [8] that Glanzmann's platelets 
show negligible serotonin secretion but a normal rate and 
extent of [Ca 2+ ]i increase in response to ADP as measured 
by fura-2 (data not shown). 
Homologous and heterologous 18 duplicate point bind- 
ing studies with ADP and ATPc~S using intact, fixed 
Glanzmann's platelets gave binding isotherms (not shown) 
and binding constants (Table 1) that were essentially iden- 
tical with those found in the present work with two normal 
controls as well as with the numerous normal controls 
previously reported [6]. The high affinity binding constants 
for the two patients calculated from homologous binding 
isotherms using ADP were 35 nM and 24400 sites per 
platelet for patient 1 and 31 nM and 9300 sites per platelet 
for patient 2. Further studies with ATPaS using platelets 
from patient 2 gave 19000-33000 high affinity 
sites/platelet in both homologous and heterologous com- 
petition studies, similar to the values found in control 
platelets [6,7]. Although our mean value for the number of 
Table 1 
Homologous and heterologous binding parameters for G lanzmann's  thrombasthenia platelets 
Kd, I K~,2 Ki, I Ki,z S 1 (s i tes/pit)  $2 (s i tes/pit)  
[3H]ADP vs. ADP control 1 20 380 - - 27205 47037 
control 2 39 1900 - - 7 698 111 478 
control a 29 5600 - - 11 202 132 755 
patient 1 35 1800 - - 24 400 182 300 
patient 2 31 360 - - 9 300 55 400 
[35S]ATPaS vs. ATPaS control 2 2.0 5500 - - 25 880 741 552 
control 2 1.2 2400 - - 22 811 430 223 
patient 2 1.4 1100 - - 26500 297000 
patient 2 3.3 5100 - - 33 000 865 000 
[35S]ATPaS vs. ADP control 2 - - 53 1300 28 186 159826 
control 2 - - 69 1800 32 105 155 863 
patient 2 - - 30 646 19 100 131 800 
patient 2 - - 100 5300 32 300 65 700 
[3H]ADP vs. 8-azido ATP (n = 3) control - - 48_+22 757+227 21000- t -3600 113000+35000 
8-azido AT  32 P vs. 8-azido ATP (n = 3) control 8 + 2 770 ± 390 - - 21 000 _ 5 300 41 000 + 10 500 
Binding isotherms with eighteen duplicate points were carried out at B/T  ratios < 0.1 and subjected to Scatchard analysis using the L IGAND program. 
To obtain this ratio the platelet concentration was 1.5 - 108/'0.5 ml in experiments with [3H]ADP and 3 • 107/0.5 ml in experiments with [35S]ATPo~S. 
Tracer concentrations were 10 nM for [ 3 H]ADP and 8-azido ATP and 2.5 nM for [ 35 S]ATP~ S with increasing concentrations of  the competing nucleotide. 
Values for K d and K i are given in nM. 
a Platelets were fixed with 1% paraformaldehyde for 30 min at 4 ° C prior binding studies (n = 2). 
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ADP binding sites on control platelets i  ~ 25 000 (n = 14) 
[6,7], the low value (9500) obtained with patient 2 is 
within biological variability and it may be noted that a 
similar value was found with control 2, although values of 
~ 25 000 were found for ATPc~ S binding in both cases. 
Because of concerns that the conditions of fixation 
might have deleterious effects on the platelet membrane 
and its nucleotide binding sites, we also carried out bind- 
ing studies on platelets fixed under the conditions used for 
flow cytometric evaluation which are generally considered 
to preserve platelet membrane antigens; namely, 1% para- 
formaldehyde/4 ° C/30 rain. Binding parameters obtained 
under these milder conditions were similar to those ob- 
tained with more prolonged fixation (Table 1). 
Steady state binding parameters for the interaction of 
8-azido ATP with plate]ets have not been previously re- 
ported. Using increasing concentrations of 8-azido ATP to 
compete in the binding; of both [3H]ADP and 8-azido 
[3-~P]ATP to fixed normal platelets, the best fit line to the 
data points, as calculated by the LIGAND program [15], 
corresponded in each case to a two site model of high and 
low affinity sites with low non-specific binding (Fig. 2). 
Calculation of the binding parameters showed that 8-azido 
ATP bound to the same number of high affinity sites 
(20000) and low affinity sites (114000) as did ADP. 
Homologous binding isotherms (8-azido [32p]ATP vs. 8- 
azido ATP) gave dissociation constants of 8 + 2 nM at the 
high affinity site and 770 _ 390 nM at the low affinity site 
while heterologous binding isotherms ([3 H]ADP vs. 8-azido 
ATP) gave values of 48 + 22 nM and 757 + 227 nM, 
respectively, atthose sites: these values are similar to those 
obtained with ADP itself (Table 1). 
3.3. Photoaffinity labelling 
With normal platelets, ATPc~S was photoincorporated 
mainly into GPIIb~x with much less incorporation into 
GPIIIa in both the Triton soluble (Fig. 3, lane 1) and 
Triton-insoluble (cytoskeleton-associated) fractions (Fig. 3, 
lane 2) but labeling was greatly reduced if the platelets 
were preincubated with EDTA (10 mM, 10 min, 37 ° C) to 
dissociate the GPIIb/Il la complex (Fig. 3, lane 3). Follow- 
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Fig. 3. Photoaffinity labeling: platelets (1.108) were labeled with 85 nM 
[35S]ATPo~S and analyzed by 7% SDS-PAGE followed by autoradiog- 
rapby. Lane l, control Triton-soluble fraction; lane 2, control Triton-in- 
soluble (cytoskeleton-associated) fraction; lane 3, photoincorporation i to 
control plate]ets previously incubated at 37 ° C, l0 rain with EDTA (10 
mM); lane 4, Glanzmann's Triton-soluble fraction; lane 5, G]anzmann's 
Triton-insoluble fraction; lane 6, control Triton-soluble fraction of normal 
platelets photoaffinity labeled with 300 nM 8-azido 132 P]ATP. Note the 
position in lane 4 of the higher molecular weight component that is 
photoaffinity labeled in Glanzmann's platelets but is not detectable in 
control platelets. Autoradiography was carried out for about one month to 
allow band detection in Glanzmann's amples although normally the 
labeled GPIIbot band in control platelets is visible within three days of 
exposure. Identical labeling patterns were observed using 140 nM 
[ 35 S]GTPot S. 
ing autoradiography for one month to obtain visible bands, 
Glanzmann's platelets gave a pattern of radiolabeling that 
would be expected in the absence of the specific labeling 
of GPIIb/IIIa and, as in control platelets labeling was 
much more evident in the Triton-soluble than in the Tri- 
ton-insoluble fractions (Fig. 3, lanes 4 and 5). ATPc~ S was 
also photoincorporated into a band of molecular weight 
(125 kDa) slightly higher than that of GPIIba (120 kDa) 
in platelets from both Glanzmann's patients (Fig. 3, lane 4) 
but was not observable in control platelets (Fig. 3, lane 1 
or 2). We have confirmed the recent report [16] that 
8-azido ADP is photoincorporated into GPIIb/IIIa in con- 
trol platelets (Fig. 3, lane 6) and that ADP is fully competi- 
tive for its photoincorporation (data not shown). 
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Fig. 2. Binding studies of 8-azido ATP with Fixed normal platelets. These studies determined 18 nucleotide concentrations in triplicate and the data was 
subjected to Scatchard analys~is u ing the LIGAND program. The platelet concentration was 1.5. 108/0.5 ml for heterologous experiments of [3H]ADP vs. 
8-azido ATP (Fig. 2, left) and 3 • 107//0.5 ml for homologous experiments of 8-azido [32 P]ATP vs. 8-azido ATP (Fig. 2, right). Tracer concentrations were 
10 nM for [3H]ADP and 2.5 nM for 8-azido [32P]ATP with increasing concentrations of competing 8-azido ATP. 
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Fig. 4. Protein blots. The Triton X-100 soluble fraction and insoluble 
residue of platelets (5.107) was subjected toSDS-PAGE and probed with 
polyclonal nti-GPIIb and ~zSI-protein A. Lane 1, control Triton-soluble 
fraction; lane 2, control Triton-insoluble fraction; lane 3, Glanzmann's 
Triton-soluble fraction; lane 4, Glanzmann's Triton-insoluble fraction. 
The arrowhead marks the expected position of the 125 kDa component 
labeled with [35 S]ATPa S. Autoradiography was carried out for 2 days for 
controls and 1 month for Glanzmann's platelets. 
3.4. Protein blott ing 
A higher molecular weight variant of GPIIb (122/128 
kDa; red/unred) has been reported in a case of Glanz- 
mann's thrombasthenia [17]. To determine whether this 
GPIIb variant corresponded to the higher molecular weight 
band detected in the photoincorporation studies with 
Glanzmann's platelets, protein blotting was carried out 
using a polyclonal anti GPI Ib/ I I Ia antibody (Fig. 4). This 
clearly showed labeling of GPIIba and GPIIIa in the 
Triton-soluble and Triton-insoluble fractions from both 
control (Fig. 4, lanes l and 2) and Glanzmann's platelets 
(Fig. 4, lanes 3 and 4) but there was not a aGPI Ib / I I Ia  
immunoreactive band at the position expected for the 125 
kDa component (arrow). 
4. Discussion 
Attempts to affinity label the platelet ADP receptor 
have been largely unsuccessful. Multiple bands were la- 
beled with 2-azidoadenosine [ fl-32p]diphospbate but the 
labeling was not suppressed by ADP nor by ATP indicat- 
ing the observed labeling was non-specific [18]. A 100 
kDa component has been labeled with the adenosine ana- 
logue 5'-p-fluorosulfonyl adenosine [2] but evidence that 
this is a PZT receptor is inconclusive. More recently, a 43 
kDa component of the platelet membrane has been shown 
to be labeled with the new photoaffinity analogue AzPet- 
ADP [10]. This observation is of particular interest since 
ADP has been shown to activate a G protein-coupled 
receptor [19] and this is the molecular weight range ex- 
pected for such receptors. P2x receptors which react with 
ATP but which are pharmacologically distinct from P2T 
receptors have also been described although not fully 
characterized [20]. 
As noted in the Introduction, there is evidence both for 
and against a role for GPI Ib/ I I Ia in ADP-mediated platelet 
activation. In order to obtain further information on this 
point we have compared control and Glanzmann's throm- 
basthenia platelets with regard to adenine nucleotide bind- 
ing and direct photoincorporation. 
Previous studies have reported that isolated membranes 
from Glanzmann's thrombasthenia pl telets bind ADP sim- 
ilarly to membranes from normal controls with either one 
or two binding sites and dissociation constants in the 
micromolar range [21,22]. Our present results, using intact 
fixed platelets, also demonstrate similarity of binding be- 
tween Glanzmann's thrombasthenia platelets and normal 
platelets but in this case we find two sites: a low affinity 
site with a dissociation constant (,-~ 2 /zM) similar to that 
previously reported [21,22] and, in addition, another site 
with an affinity (35 riM) about two orders of magnitude 
greater and similar to that which we found in our other 
studies on nucleotide binding [6,7]. These differences could 
arise if formaldehyde fixation enhances the affinity for 
ADP at the binding site which would appear to be unlikely 
or, alternatively, if membrane isolation results in the loss 
of the high affinity binding component. This question 
cannot be resolved by use of intact unfixed platelets ince 
we have shown that it is not possible to obtain steady state 
binding conditions in that case due to ligand degradation 
[4]. Moreover, we have found that changing the conditions 
of fixation to those known to retain immunologic function 
in flow cytometric experiments does not affect the nu- 
cleotide binding parameters. 
About 90% of the ADP bound to fixed platelets would 
be present at the high affinity binding site [4]. This binding 
site has several similarities to what would be expected for 
an ADP receptor in fresh, unfixed platelets: namely, (i) the 
dissociation constant at the high affinity binding site (35 
nM) is in the concentration range (~ 50 nM) at which 
ADP-induced shape change is observed; (ii) nucleotides 
known to be antagonists for ADP-induced activation com- 
pete in ADP binding; (iii) p-chloromercuribenzoate nd
5'-p-fluorosulfonylbenzoyl adenosine were shown to in- 
hibit the binding of ADP to fixed platelets and are known 
to inhibit ADP-induced responses of fresh platelets; (iv) 
8-bromo ADP was shown to inhibit ADP binding to fixed 
platelets and was then shown also to inhibit ADP-induced 
activation of fresh platelets [4]. 
ADP analogues have strict structural requirements in
order to act as platelet agonists and only substitution i  the 
C2 position is tolerated. However, previous studies from 
this laboratory have shown that a wide variety of purine 
and pyrimidine analogues of ADP can act as antagonists of 
ADP-induced activation and can bind to intact fixed 
platelets with affinities similar to those of ADP itself 
[4,6,7]. Several of these nucleoside triphosphates have 
been directly photoincorporated into unfixed platelets fol- 
lowing ultraviolet irradiation, specifically into a domain in 
GPIIba beginning at Tyr-198 and with little incorporation 
into GPIIIa [6,7]. 
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We have shown that ATPaS competes in the ADP-in- 
duced shape change of Glanzmann's thrombasthenia and is 
thus a valid probe for photoincorporation studies. Although 
there is the possibility of nucleotide metabolism when 
using fresh platelets, and this is the rationalization for 
using fixed platelets in the binding studies, possible 
metabolic effects have been minimized by carrying out 
photoincorporation studies at ice-bath temperatures. More- 
over, ADPa S formed as the metabolic product of ATPa S 
would also bind to the ADP binding site, albeit with lower 
affinity and could, therefore, also be photoincorporated 
into GPIIba. In the absence of GPIIb/IIIa, only one 
additional photolabeled bands is observed at 125 kDa. We 
do not know the relevance of this photoaffinity labeled 
band but it does not react with anti GPIIb/IIIa antibodies. 
With Glanzmann's platelets the amount of direct photoin- 
corporation of [35S]ATP~eS into GPIIba was about 7% of 
that in normal controls, which is in agreement with the 
amount of GPIIb/IIIa detected in these two patients [14]. 
In contrast, the number of high affinity ADP binding sites 
found in Glanzmann's thrombasthenia pl telets (~ 25 000) 
are quantitatively identical to those found in normal 
platelets (22 300 ___ 4100). These numbers agree reasonably 
well with the number of GPIIb/IIIa complexes found from 
the binding of fibrinogen to stimulated platelets (14000- 
38000) [23-25] although lower than the approximately 
40 000 sites reported for the binding of anti-GPIIb mono- 
clonal antibodies [26,2711. These numbers may suggest a 
stoichiometric ratio between the number of high affinity 
ADP binding sites and the number of GPllb/IIIa com- 
plexes on the surface of normal platelets. 
Based on the inhibitory effects of 8-bromo ADP on 
platelet activation [4], the photoactivatable analogue 8- 
azido ATP has recently been shown to be photoincorpo- 
rated almost equally into GPIIb and GPIIIa and the speci- 
ficity of labeling was examined by irradiation in the 
presence of added 1 mM ATP [16]. As we have previously 
emphasized [6,7], careful controls are required to ensure 
that any observed ecrease in photoincorporation s due to 
competition and not to a reduced egree of activation due 
to absorption of ultraviolet light by the increased concen- 
tration of total nucleotide: in general, this means that the 
incident ultraviolet light irradiating the control must be 
passed through a filter comprising a petri dish containing 
the competing nucleotide in the same concentration asthat 
present in the experimental sample. 
In the present studies, we have established that 8-azido 
ATP has similar binding parameters to ADP at the high 
and low affinity sites in control platelets, we have con- 
firmed that it is incorporated approximately equally into 
GPIIb and GPIIIa and we have shown that this incorpora- 
tion is inhibited by ADP when precautions are taken to 
ensure qual irradiation as outlined above. 
Direct photoincorporation f purine nucleotides proba- 
bly arises from photoactivation of the C8 position and, 
with ATPaS, appears to be selective for photolabeling 
GPIIba [7]. However, when an azido group is present in 
the C8 position to act as a linker, photolabeling is essen- 
tially equal for GPIIba and GPIIIa. These studies uggest 
that precise configurational relationships between GPIIb, 
GPIIIa and the platelet nucleotide binding site are required 
for photoincorporation and are consistent with our observa- 
tions that dissociation of the GPIIb/IIIa complex with 
EDTA results in decreased photoincorporation into both 
components. 
With platelets, the ribose phosphate side chain appears 
to be an important determinant of binding affinity since 
ATP binds equally with ADP while ATPaS binds with 
about 10-fold greater affinity. The requirements for the 
structure of the nucleoside base appear, however, to be 
relatively permissive and the 5'-(l-thiotriphosphates) of 
guanosine (GTPaS), adenosine (ATPaS), cytidine 
(CTPa S) and uridine (UTPa S) all show comparable bind- 
ing parameters in fixed platelets and comparable ability to 
inhibit ADP-induced shape change and to be photoincorpo- 
rated into GPIIba in fresh unfixed platelets [6]. In the 
present experiments, we have found similar patterns of 
photoincorporation with Glanzmann's platelets using either 
ATPaS or GTPaS. These results suggest hat ADP, or 
other nucleotides, may bind in platelets through their ri- 
bose phosphate moieties at an as-yet-unidentified binding 
site. Since ADP would be in its extended anti configura- 
tion, the domain most distal to the ribose phosphate bind- 
ing moiety would be the C8 position which is thought o 
be the position that is activated when nucleotides are 
irradiated with ultraviolet light [28]. Under normal condi- 
tions, GPIIba may be in sufficient proximity to this 
extended nucleotide configuration that it could become 
covalently labeled through the C8 position following pho- 
toactivation of the nucleotide. Similar crosslinking of ap- 
proximated omains in skeletal myosin fragment 1 with a 
bifunctional ATP analogue has been reported [29]. 
These experiments support he hypothesis that the ADP 
binding site of platelets is distinct from GPIIba but sug- 
gest that the two may be in sufficiently close proximity 
that ADP could interact with both under conditions of 
photoaffinity labeling with ADP or its analogues. This is 
consistent with the report that Ca 2+ influx in response to 
ADP occurs predominantly via a channel closely adjacent 
to the GPIIb/IIIa complex [8]. The nature of this impor- 
tant receptor remains to be elucidated. 
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